The ChemoPRO® Feasibility study; v1.0
Research type
Research Study
Full title
Electronic monitoring of cancer symptoms and treatment-related toxicity: A feasibility study of using the ChemoPRO® app in an oncology setting
IRAS ID
345756
Contact name
Christel McMullan
Contact email
Sponsor organisation
University of Birmingham
Clinicaltrials.gov Identifier
n/a, n/a
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Patients living with cancer may experience many symptoms related to their disease and treatment-related side effects.(1) To understand these, it is important to capture patients’ perspectives of their own health. This is done using Patient Reported Outcome Measures (PROMs). PROMs are questionnaires, completed by patients without any outside help, which measure patients’ own experience of their health, disease-related symptoms and treatment-related side effects.(2)
PROMs can be completed on paper or electronically on a smartphone/tablet (ePROMs). Electronic PROMs have the advantage of reducing data entry burden and errors. It also enables clinicians to check of patient information remotely, and can reduce patient burden.(3)
ChemoPRO® is a mobile application which is developed to be used by patients to report their symptoms by answering online questionnaires. It was designed by CIS Oncology, a med tech company based in the UK and has several features:(4)
- Linked with the ChemoCare® platform (an electronic chemotherapy prescribing and patient management system)
- Maintains contact between clinical teams and patients between visits.
- Allows patients to record symptoms and wellness which can be accessed by the healthcare team.
- Allows patients to access appointments and medication reminders.(5)The aim of this study is to assess the feasibility and acceptability of using the CIS Oncology ChemoPRO® app and the ChemoCare® electronic platform in an NHS oncology clinical setting.
Methods:
Patients will use the ChemoPRO app to complete questionnaires about their symptoms. Semi-structured interviews will also be conducted with patients living with cancer taking part in the study and any decliners, and clinicians involved in the study.1. Basch E. et al. JCO Clin Cancer Inform. 2020;4:947-57.
2. Black N. BMJ. 2013;346.
3. Basch E. et al. J Clin Oncol. 2016;34(6):557-65.
4. CIS Oncology. Available from: https://www.cis-healthcare.com/
5. McMullan C. et al. Heliyon. 2023;9(6):e16453.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
24/EE/0249
Date of REC Opinion
7 Nov 2024
REC opinion
Further Information Favourable Opinion